The introduction of the drug in Oz is creating significant excitement within the medical community. This novel dual agonist – targeting both GLP-1 and GIP receptors – presents a seemingly effective option for https://socialbraintech.com/story7053074/new-retatrutide-australia-a-possible-promising-hope-for-weight-reduction